Literature DB >> 12718730

Drug delivery to the retina: challenges and opportunities.

Sridhar Duvvuri1, Soumyajit Majumdar, Ashim K Mitra.   

Abstract

Retinal drug delivery is a challenging area in the field of ophthalmic drug delivery. An ideal drug delivery system for the retina and vitreous humor has not yet been found, despite extensive research. Drug delivery to retinal tissue and vitreous via systemic administration is constrained due to the presence of a blood-retinal barrier (BRB) which regulates permeation of substances from blood to the retina. Although intravitreal administration overcomes this barrier, it is associated with several other problems. In recent years, transporter targeted drug delivery has become a clinically significant drug delivery approach for enhancing the bioavailabilities of drug molecules with poor membrane permeability characteristics. Various nutrient transporters, which include peptide, amino acid, folate, monocarboxylic acid transporters and so on, have been reported to be expressed on the retina and BRB. Prodrug derivatisation of drug molecules which target these transporters could result in enhanced ocular bioavailability. Highlighted in this review are various strategies currently employed for drug delivery to the posterior chamber, and novel opportunities that can be exploited to enhance ocular bioavailability of drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12718730     DOI: 10.1517/14712598.3.1.45

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  41 in total

1.  Diffusion Regulation in the Vitreous Humor.

Authors:  Benjamin Tillmann Käsdorf; Fabienna Arends; Oliver Lieleg
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

Review 2.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Noninvasive molecular neuroimaging using reporter genes: part II, experimental, current, and future applications.

Authors:  T F Massoud; A Singh; S S Gambhir
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-13       Impact factor: 3.825

Review 4.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

5.  Can ultrasound solve the transport barrier of the neural retina?

Authors:  Liesbeth Peeters; Ine Lentacker; Roosmarijn E Vandenbroucke; Bart Lucas; Joseph Demeester; Niek N Sanders; Stefaan C De Smedt
Journal:  Pharm Res       Date:  2008-07-23       Impact factor: 4.200

6.  Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

7.  Solution formulation development of a VEGF inhibitor for intravitreal injection.

Authors:  Michelle T Marra; Penney Khamphavong; Peter Wisniecki; Hovhannes J Gukasyan; Katsuhiko Sueda
Journal:  AAPS PharmSciTech       Date:  2011-02-11       Impact factor: 3.246

8.  Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells.

Authors:  Viral Kansara; Durga Paturi; Shuanghui Luo; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2007-12-23       Impact factor: 5.875

9.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

Review 10.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.